NeoStem to Present at Multiple Conferences in November

        Print
| Source: NeoStem Inc.

NEW YORK, Oct. 31, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy market, today announced that Company management and management of its subsidiary, Progenitor Cell Therapy ("PCT"), have been invited to present at multiple conferences in November.

American Heart Association – Scientific Sessions 2012

  • Date: November 6, 2012, 11:00 AM PST
  • Venue: Los Angeles Convention Center, Los Angeles, CA
  • Session Title: Cardiovascular Regeneration: From Bench to Clinic
  • Presenter: Jonathan Sackner-Bernstein, M.D., FACC, Vice President, Clinical Development and Regulatory Affairs of NeoStem will present an abstract titled "Predictors of Response to Intracoronary Delivery of CD34+CXCR4+ Enriched Bone Marrow Derived Stem Cells (AMR-001) Early After STEMI"

2012 ISPE Annual Meeting: Global GMP Solutions through Innovation and Transformation

  • Date: November  12, 2012, 3:30 PM PST
  • Venue: Marriott Marquis, San Francisco, CA
  • Presenter: Sanjin Zvonic, Ph.D., Director of Technology and Business Development of PCT, will speak on "Immunotherapies and Tissue Culture Manufacturing Technologies" within the Biotechnology Executive Series Session

Lazard Capital Markets 9th Annual Healthcare Conference

  • Date: November 14, 2012, 10:00 AM EST
  • Venue: The Pierre Hotel, New York, NY
  • Presenter: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem will give a company presentation.

New York Society of Security Analysts' 16th Annual "Investing in Life Sciences" Conference

  • Date: November 29, 2012, 11:15 AM EST
  • Venue: NYSSA Conference Center, New York, NY
  • Presenters: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem will give a company presentation.

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

For more information, please visit www.neostem.com.

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its contract development and manufacturing ("CDMO") business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. Forward looking statements also include statements with respect to satisfying all conditions to closing the disposition of Erye, including receipt of all necessary regulatory approvals in the PRC. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including but not limited to matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Trout Group
Gitanjali Jain Ogawa, Vice President
Phone: +1-646-378-2949
Email: